Kuros Biosciences announced enrollment of the first patient in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlled, multi-center study to assess the safety and performance of MagnetOs compared to autograft in patients undergoing hindfoot or ankle fusions. Subtalar fusion will be one of many surgical approaches included in the study.
ASTRA is part of Kuros’ expanding global extremities strategy and will include sites in the U.S., Australia, New Zealand, Europe and/or the Middle East.
Approximately 126 patients undergoing hindfoot or ankle fusions will be prospectively enrolled and randomized to receive treatment in either the MagnetOs arm (MagnetOs Putty or MagnetOs Easypack Putty used standalone, not mixed with other bone grafting materials) or the autograft arm.
Chris Fair, Chief Executive Officer of Kuros Biosciences, stated: “Building on the strength of our ongoing Level I PROOF and PRECISE clinical trials in posterolateral spine fusion, ASTRA extends our clinical evidence portfolio into foot and ankle. We’re proud to continue advancing the science of bone healing into new anatomical regions where surgeons need reliable solutions for their patients.”
The study name ASTRA was inspired by astragalus, the historical term for what is now known as the talus or ankle bone, underscoring the study’s focus on improving outcomes in ankle and hindfoot fusion procedures.
Kuros Biosciences announced enrollment of the first patient in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlled, multi-center study to assess the safety and performance of MagnetOs compared to autograft in patients undergoing hindfoot or ankle fusions....
Kuros Biosciences announced enrollment of the first patient in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlled, multi-center study to assess the safety and performance of MagnetOs compared to autograft in patients undergoing hindfoot or ankle fusions. Subtalar fusion will be one of many surgical approaches included in the study.
ASTRA is part of Kuros’ expanding global extremities strategy and will include sites in the U.S., Australia, New Zealand, Europe and/or the Middle East.
Approximately 126 patients undergoing hindfoot or ankle fusions will be prospectively enrolled and randomized to receive treatment in either the MagnetOs arm (MagnetOs Putty or MagnetOs Easypack Putty used standalone, not mixed with other bone grafting materials) or the autograft arm.
Chris Fair, Chief Executive Officer of Kuros Biosciences, stated: “Building on the strength of our ongoing Level I PROOF and PRECISE clinical trials in posterolateral spine fusion, ASTRA extends our clinical evidence portfolio into foot and ankle. We’re proud to continue advancing the science of bone healing into new anatomical regions where surgeons need reliable solutions for their patients.”
The study name ASTRA was inspired by astragalus, the historical term for what is now known as the talus or ankle bone, underscoring the study’s focus on improving outcomes in ankle and hindfoot fusion procedures.
Copy to clipboard 
